Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Tue, 09.07.2024
LION E-Mobility AG
Successful AMG // Surprisingly strong JV performance
Topic: During the last weeks, LION published its FY23 annual report and
hosted its AGM. Here are the key takeaways:
FY23 marked a milestone as the company transformed itself into an automated
manufacturer of high-quality battery packs for mobility and storage
solutions through the acquisition [ … ]
Mon, 08.07.2024
Rosenbauer International AG
Global warming drives demand in the firefighting industry
Topic: Global warming has caused a severe rise in natural disasters such as
floods, wildfires and storms in the last decades. The research institute
“Our World in Data” by the University of Oxford indicates an increase from
83 recorded natural disaster events in 1970 to 410 i [ … ]
Wed, 03.07.2024
Energiekontor AG
First Berlin Equity Research hat ein Research Update zu Energiekontor AG
(ISIN: DE0005313506) veröffentlicht. Analyst Dr. Karsten von Blumenthal
bestätigt seine BUY-Empfehlung und bestätigt sein Kursziel von EUR 126,00.
Zusammenfassung:
In den letzten Wochen ist der Aktienkurs von Energiekontor um fast 20%
gesunken, da sich das S [ … ]
Fri, 28.06.2024
Singulus Technologies AG
Recovery of order intake should support growth in FY24e
Topic: After a temperate demand from customers in the last fiscal year,
FY24e looks more encouraging. With several promising projects in the
pipeline, signaled by a strong order intake of € 33m in the first quarter
(vs. € 43m in entire FY23), we expect better results for FY24e.
[ … ]
Fri, 28.06.2024
Einhell Germany AG
Q2 prelims in line with expectations // FY24e guidance confirmed
Yesterday, Einhell released ad-hoc news revealing that sales between
January and May 2024 amounted to € 478.2m (+11.6% yoy). The company further
expects sales for H1'24 to be € 565m (+7.4% yoy; eNuW: € 562m) and EBT
margin to be 8.5% (-10bps yoy; eNuW: 8.3%). Theref [ … ]
Thu, 27.06.2024
Nabaltec AG
Further op. improvements // FY guidance conservative
Topic: Despite the recent 30% share price increase since the low in March,
Nabaltec remains on our Alpha List with the key reasons for it being (1)
further operational improvements in Q2 and a too conservative FY guidance,
(2) the promising optionality of boehmite and (3) an attractive valuat [ … ]
Wed, 26.06.2024
UmweltBank AG
- Return to profitability expected after transformation year 2024
- Realignment bears fruit
- Interest margin expected to bottom out
With the publication of their 2023 Annual Report, UmweltBank AG has
confirmed the preliminary figures published in March. As previously
announced, new lending business declined and was down from the previous
[ … ]
Wed, 26.06.2024
Westwing Group SE
On track to strengthen the premium H&L one-stop shop in 2024
While 2024 revenue and active customer growth will be affected by
headwinds in its International segment resulting from a deliberate and
strategic adjustment of the product assortments in Spain and Italy by a low
to mid single-digit percentage figure to enhance future scalability [ … ]
Mon, 24.06.2024
Verve Group SE
Jun acquisition ensures significant sales and earnings growth and a
significant strengthening of the demand side; the integration of the
acquisition opens up considerable sales synergies; significant increase in
forecasts and price target; 'BUY' rating confirmed
On 18 June 2024, Verve Group SE (Verve) announced the signing of an
agreement [ … ]
Mon, 24.06.2024
APONTIS PHARMA AG
First Berlin Equity Research on 24/06/2024 initiated coverage on APONTIS
PHARMA AG (ISIN: DE000A3CMGM5/ Bloomberg: APPH GR). Analyst Christian
Orquera placed a BUY rating on the stock, with a EUR 17.00 price target.
Abstract:
Apontis Pharma AG (Apontis) is a leading specialty pharmaceutical company
focusing on the development and marketing of a [ … ]
